Aligos Therapeutics Inc (5WK0)

Currency in EUR
6.35
-0.55(-7.97%)
Closed·
5WK0 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
6.356.35
52 wk Range
3.6244.80
Key Statistics
Bid/Ask
6.80 / 7.05
Prev. Close
6.9
Open
6.35
Day's Range
6.35-6.35
52 wk Range
3.62-44.8
Volume
25
Average Volume (3m)
585
1-Year Change
-31.94%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
5WK0 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Aligos Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Aligos Therapeutics Inc Company Profile

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Compare 5WK0 to Peers and Sector

Metrics to compare
5WK0
Peers
Sector
Relationship
P/E Ratio
0.0x0.0x0.0x
PEG Ratio
0.000.000.00
Price/Book
0.0x0.0x0.0x
Price / LTM Sales
0.0x0.0x0.0x
Upside (Analyst Target)
0.0%0.0%0.0%
Fair Value Upside
Unlock0.0%0.0%Unlock

Earnings

Latest Release
-
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

5WK0 Income Statement

People Also Watch

119.78
CRDO
+2.08%
170.92
ALAB
-1.99%
47.710
ASTS
-7.88%
2.6200
ABVC
-8.39%
152.93
CRCL
-5.43%

FAQ

What Stock Exchange Does Aligos Therapeutics Inc Trade On?

Aligos Therapeutics Inc is listed and trades on the Frankfurt Stock Exchange stock exchange.

What Is the Stock Symbol for Aligos Therapeutics Inc?

The stock symbol for Aligos Therapeutics Inc is "5WK0."

What Is the Aligos Therapeutics Inc Market Cap?

As of today, Aligos Therapeutics Inc market cap is 42.40M.

What Is Aligos Therapeutics Inc's Earnings Per Share (TTM)?

The Aligos Therapeutics Inc EPS (TTM) is 0.00.

From a Technical Analysis Perspective, Is 5WK0 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Aligos Therapeutics Inc Stock Split?

Aligos Therapeutics Inc has split 0 times.

What is the current trading status of Aligos Therapeutics Inc (5WK0)?

As of 08 Aug 2025, Aligos Therapeutics Inc (5WK0) is trading at a price of 6.35, with a previous close of 6.90. The stock has fluctuated within a day range of 6.35 to 6.35, while its 52-week range spans from 3.62 to 44.80.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.